Table 2.

Cox regression analysis for predicting unfavorable biopsy conversion at annual surveillance biopsy examination in an active surveillance cohort

Variable	Patients (n)	Univariate		Multivariate Model 1		Multivariate Model 2
		HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Serum
Prostate Health Index			.003		.047
≤34.2	38	1.00		1.00
>34.2	33	2.65 (1.39–5.07)		2.00 (1.008–3.97)
[−2]proPSA/%fPSA			.004				.036
≤0.7	36	1.00				1.00
>0.7	35	2.65 (1.36–5.16)				2.15 (1.05–4.38)
DNA content
BA excess of OD			.019		.023		.018
≤25	59	1.00		1.00		1.00
>25	12	2.58 (1.17–5.68)		2.69 (1.15–6.32)		2.80 (1.19–6.57)
CA SD of OD			.002		.004		.003
≤4	18	1.00		1.00		1.00
>4	53	5.36 (1.89–15.24)		4.87 (1.66–14.24)		4.97 (1.70–14.50)

HR, hazard ratio; CI, confidence interval; PSA, BA, benign-adjacent; OD, optical density; CA, cancer; SD, standard deviation.